Immunobiology of cholangiocarcinoma

Loeuillard, Emilien; Conboy, Caitlin B.; Gores, Gregory J.; Rizvi, Sumera

doi:10.1016/j.jhepr.2019.06.003

Cited by 91 publications

(97 citation statements)

References 129 publications

(155 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is great interest in combination therapies, where immune checkpoint blockade is coupled with existing or experimental drugs with a different mechanism of action or even with locoregional treatments. ( 88 ) Therapeutic approaches are required for the development of universal CCA treatments that are not limited to phenotypes of CCA tumors or microenvironment. EVs have potential to be used as a therapeutic tool to deliver cargo mediators or drugs into CCA tumors or cells in the tumor microenvironment.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

The Tumor Microenvironment in Cholangiocarcinoma Progression

et al. 2020

View full text Add to dashboard Cite

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

The Tumor Microenvironment in Cholangiocarcinoma Progression

et al. 2020

View full text Add to dashboard Cite

“…CCA microenvironment show different gene expression profiles for immune checkpoint pathways, and though, effects of immunotherapy may be limited to small numbers of patients. On the other hand, there is great interest in combination therapies, where immune checkpoint blockade is coupled with existing or experimental drugs or even with loco-regional treatments [ 46 , 47 ].…”

Section: Cca Biology Tumoral Heterogeneity and Molecular Charactementioning

confidence: 99%

A New Option for the Treatment of Intrahepatic Cholangiocarcinoma: Percutaneous Hepatic Perfusion with CHEMOSAT Delivery System

Ferrucci

Cocorocchio

Bonomo

et al. 2021

Cells

View full text Add to dashboard Cite

Liver metastases are a major management problem; since they occur in tumors of different origin, they are often multiple, difficult to visualize and can lie dormant for many years. Patients with liver metastases usually die of their disease, mostly due to liver failure, since systemic treatments are unable to eradicate micro-metastasis, and interventional loco-regional procedures cannot treat all existing ones. Cholangiocarcinoma (CCA) is the second most common primary liver tumor, showing a poor overall prognosis. When resection is not possible, treatment options include tumor-focused or local ablative therapy, organ-focused or regional therapy and systemic therapy. We reviewed available loco-regional therapeutic options, with particular focus on the CHEMOSAT® Melphalan/Hepatic Delivery System (CS-HDS), which is uniquely positioned to perform a percutaneous hepatic perfusion (PHP), in order to treat the entire liver as a standalone or as complementary therapy. This system isolates the liver circulation, delivers a high concentration of chemotherapy (melphalan), filters most chemotherapy out of the blood and is a repeatable procedure. Most CS-HDS benefits are demonstrated in liver-predominant diseases, like liver metastasis from uveal melanoma (UM), hepatocarcinoma (HCC) and CCA. More than 650 procedures have been performed in Europe to date, mostly to treat liver metastases from UM. In CCA, experience is still limited, but retrospective analyses have been reported, while phase II and III studies are closed, waiting for results or ongoing.

show abstract

“…CCAs are desmoplastic tumors with an abundant tumor‐immune microenvironment characterized by immunosuppressive TAMs and MDSCs. ( 70 ) An effective approach will likely use a combination of immunotherapies targeting the innate and adaptive immune response in CCA. Combination immunotherapy strategies using ICI are currently under investigation in multiple ongoing clinical trials (Tables 1‐5).…”

Section: Immunotherapy In Liver Cancermentioning

confidence: 99%